Altimmune Inc. (ALT)
| Bid | 5.11 |
| Market Cap | 400.09M |
| Revenue (ttm) | 20K |
| Net Income (ttm) | -95.06M |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -3.88 |
| Forward PE | -3.06 |
| Analyst | Buy |
| Ask | 5.3 |
| Volume | 1,888,854 |
| Avg. Volume (20D) | 2,467,883 |
| Open | 5.25 |
| Previous Close | 5.25 |
| Day's Range | 5.10 - 5.37 |
| 52-Week Range | 3.55 - 11.16 |
| Beta | 0.89 |
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica...
Analyst Forecast
According to 8 analyst ratings, the average rating for ALT stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 361.98% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · accessnewswire.com
ALT5 Sigma Wins Best Payment Provider Award at SiGMA Eurasia 2025ALT5 Sigma honored for delivering enterprise-grade crypto payment solutions that enhance security, compliance, and transaction efficiency LAS VEGAS, NEVADA / ACCESS Newswire / February 26, 2025 / ALT5...